A phase II trial is underway to investigate the safety and efficacy of the JAK1 selective inhibitor in SLE in monotherapy or in combination with a Bruton’s tyrosine kinase (BTK) inhibitor-elsubrutinib (NCT03978520) [83]. Here, JAK1 is linked to systemic lupus erythematosus.